These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 8272220

  • 1. Effectiveness of low-dose erythropoietin in predialysis chronic renal failure patients.
    Mitwalli A, Abuaisha H, al Wakeel J, al Mohaya S, Alam AA, el Gamal H, Fayed H.
    Nephrol Dial Transplant; 1993; 8(10):1085-8. PubMed ID: 8272220
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy.
    Schwartz AB, Kahn SB, Kelch B, Kim KE, Pequignot E.
    Clin Nephrol; 1992 Nov; 38(5):283-9. PubMed ID: 1451342
    [Abstract] [Full Text] [Related]

  • 5. Effect rHuEpo on predialysis CRF patients: study of 45 cases.
    Islam S, Rahman H, Rashid HU.
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):83-7. PubMed ID: 16967814
    [Abstract] [Full Text] [Related]

  • 6. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A.
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [Abstract] [Full Text] [Related]

  • 7. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN, Sinha DK, Almeida AF, Pathare AV.
    J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
    Marusza W, Matuszkiewicz-Rowińska J, Tomik Z, Andrzejewski A, Rokicka M, Paszkowska M, Drygieniec D, Bobilewicz D, Zawadzka M, Abbas-Fatah A.
    Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
    [Abstract] [Full Text] [Related]

  • 10. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
    Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW.
    N Engl J Med; 1989 Jul 20; 321(3):158-63. PubMed ID: 2747747
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
    Alexander SR.
    Am J Kidney Dis; 1991 Oct 20; 18(4 Suppl 1):42-53. PubMed ID: 1928079
    [Abstract] [Full Text] [Related]

  • 13. Importance of iron saturation for erythropoietin responsiveness in chronic peritoneal dialysis.
    Jonnalagadda V, Bloom EJ, Raja RM.
    Adv Perit Dial; 1997 Oct 20; 13():113-5. PubMed ID: 9360662
    [Abstract] [Full Text] [Related]

  • 14. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
    Boran M, Dalva I, Yazicioğlu A, Akbay E, Cetin S.
    Int Urol Nephrol; 1993 Oct 20; 25(2):197-203. PubMed ID: 8365853
    [Abstract] [Full Text] [Related]

  • 15. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H, Mimura T, Honda N.
    Hemodial Int; 2008 Oct 20; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
    Qureshi IZ, Abid K, Ambreen F, Qureshi AL.
    Saudi Med J; 2007 Feb 20; 28(2):193-6. PubMed ID: 17268695
    [Abstract] [Full Text] [Related]

  • 17. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
    Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G.
    J Assoc Physicians India; 2003 Feb 20; 51():170-4. PubMed ID: 12725261
    [Abstract] [Full Text] [Related]

  • 18. Seizures in haemodialysis patients treated with recombinant human erythropoietin.
    Edmunds ME, Walls J, Tucker B, Baker LR, Tomson CR, Ward M, Cunningham J, Moore R, Winearls CG.
    Nephrol Dial Transplant; 1989 Feb 20; 4(12):1065-9. PubMed ID: 2517327
    [Abstract] [Full Text] [Related]

  • 19. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study.
    Faller B, Slingeneyer A, Waller M, Michel C, Grützmacher P, Müller HP, Barany P, Grabensee B, Issad B, Schmitt H.
    Clin Nephrol; 1993 Sep 20; 40(3):168-75. PubMed ID: 8403573
    [Abstract] [Full Text] [Related]

  • 20. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.
    Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK.
    Nephrol Dial Transplant; 2001 Feb 20; 16(2):307-12. PubMed ID: 11158405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.